BESTT Women's Study
Research type
Research Study
Full title
Bone Evaluation in women over 40 who Switch from Truvada/NNRTI to Triumeq
IRAS ID
180161
Contact name
Frank Post
Contact email
Sponsor organisation
Kings College Hospital
Eudract number
2015-005297-37
Duration of Study in the UK
3 years, 5 months, 1 days
Research summary
Research Summary
Treatment of HIV has been revolutionised by successful therapy with Antiretroviral Therapy (ART). This means that people living with HIV (PLWH) who are treated before significant immunodeficiency are expected, with life-long treatment, to live a normal lifespan. ART may result in reductions in bone mineralisation and kidney function, although this remains poorly studied in women. This trial will examine the effects of an ART switch on bone mineralisation and kidney function. Preservation of bone mineral density is particularly relevant in the study population (older women) as ART may compound the reductions in bone mineral density that occur as a result of the menopause and as such contribute to fracture risk in this population.
Summary of Results
Women aged 40 years and over who switched to a Dolutegravir-containing anti-retroviral regimen experienced improvements of lumbar spine bone mineral density and proteinuria.
REC name
London - City & East Research Ethics Committee
REC reference
16/LO/0019
Date of REC Opinion
10 Feb 2016
REC opinion
Further Information Favourable Opinion